Comparative Pharmacology
Head-to-head clinical analysis: EXTINA versus M ZOLE 7 DUAL PACK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EXTINA versus M ZOLE 7 DUAL PACK.
EXTINA vs M-ZOLE 7 DUAL PACK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antifungal agent that inhibits the enzyme 14α-demethylase, blocking the conversion of lanosterol to ergosterol, an essential component of fungal cell membranes.
M-ZOLE 7 DUAL PACK contains miconazole, an imidazole antifungal that inhibits fungal lanosterol 14α-demethylase (CYP51), blocking ergosterol synthesis, disrupting fungal cell membrane integrity, and increasing permeability, leading to cell death.
2.5% to 3.5% solution applied topically twice daily for 4 weeks.
Adults: One vaginal tablet (containing 500 mg metronidazole and 150 mg miconazole nitrate) inserted vaginally once daily at bedtime for 7 days.
None Documented
None Documented
Terminal elimination half-life is approximately 24-32 hours in adults, allowing once-daily dosing. Half-life may be prolonged in patients with renal impairment.
Terminal half-life approximately 48–72 hours. Prolonged in renal impairment (up to 72–120 hours in ESRD), requiring dose adjustment.
Primarily renal excretion of unchanged drug (approximately 80-90% of the absorbed dose), with minor hepatic metabolism and fecal elimination (<10%).
Primarily renal (80% unchanged drug, 20% as metabolites); biliary/fecal excretion is minimal (<5%).
Category C
Category C
Antifungal
Antifungal